Abstract
Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.
| Original language | English |
|---|---|
| Article number | 102265 |
| Journal | Journal of Nuclear Cardiology |
| Volume | 50 |
| Early online date | 9 Jun 2025 |
| DOIs | |
| Publication status | Published - Aug 2025 |
Bibliographical note
Copyright © 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).Fingerprint
Dive into the research topics of 'Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver